VLA1553, commercially known as Ixchiq, has received USFDA clearance and will be launched in India — which has seen high number of chikungunya cases — after ‘regulatory talks with DCGI’.
Trial of live-attenuated vaccine VLA1553 was conducted in US, with high seroprotection rates observed in participants up to 180 days after vaccination. Study published in 'The Lancet'.
Trials for the vaccine, which International Vaccine Institute is developing in partnership with Bharat Biotech, are also expected to begin in Panama and Colombia by September.
Researchers from Chulalongkorn University in Thailand find that chikungunya strain identified in Thailand has mutations that originated in India and Bangladesh
Disenfranchisement by institutional fiat is profoundly undemocratic. The effect of the ECI's new documentary process in Bihar will tilt the scales in favour of the BJP.
Mini deal will likely see no cut in 10% baseline tariff on Indian exports announced by Trump on 2 April, it is learnt, but additional 26% tariffs are set to be reduced.
India-Russia JV is also racing to deliver 7,000 more AK-203 assault rifles by 15 Aug. These are currently being made with 50% indigenisation and this will surge to 100% by 31 December.
Public, loud, upfront, filled with impropriety and high praise sometimes laced with insults. This is what we call Trumplomacy. But the larger objective is the same: American supremacy.
COMMENTS